DYNC2LI1

Across TCGA pan-cancer cohorts, DYNC2LI1 mass-spec protein differs between tumor and matched normal tissue in 3 of 18 cancer types tested, making tumor–normal expression one of DYNC2LI1’s most consistent transcriptional readouts.

The strongest signal is observed in lung adenocarcinoma (LUAD), where DYNC2LI1 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types DYNC2LI1 is over-expressed in tumor, although a few such as LUAD and PDAC show the opposite, repressed pattern.

LUAD, PDAC, and LSCC are the cancer types where DYNC2LI1 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in DYNC2LI1 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LUAD	Female	All	−0.354	<.001	9	view →
PDAC	All	All	−0.405	.005	4	view →
LSCC	All	All	−0.135	.002	3	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 3 strongest of 3 lineages.

DYNC2LI1–LUAD

Open the LUAD breakdown →